Vectus Biosystems (ASX:VBS)
ASX announcement history & article coverage
Transparent by design.
Announcments by Vectus Biosystems (ASX:VBS) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
VBS Engages CHRS as Regulatory Agent for FDA Submissions
Vectus appoints Cardinal Health as US FDA regulatory agent for VB0004
Cleansing Notice
Application for quotation of securities - VBS
CEO Investor Webinar
Change in substantial holding
Change in substantial holding KHPL
Cleansing Notice
Application for quotation of securities - VBS
Proposed issue of securities - VBS
Placement of Shares
Vectus raises $0.8M to accelerate VB0004 clinical trial and drug development
Updated Corporate Presentation
Cleansing Notice
Application for quotation of securities - VBS
Cleansing Notice
Application for quotation of securities - VBS
Notification regarding unquoted securities - VBS
Appointment of Dr Tara Speranza as CEO & CTO
Vectus appoints Dr Tara Speranza as CEO and CTO with performance-linked incentives
Quarterly Activities & Appendix 4C Cash Flow Reports
Vectus sells VB4-P5 to XORTX, gains equity; advances licensing efforts for VB0004 with reduced costs
VB4-P5 Renal Compound Transaction Settled
Vectus completes sale of VB4-P5 renal compound to XORTX, gains 9.9% stake
